“Much of the current artificial intelligence in healthcare is primarily black box: algorithms make a prediction, but they don’t explain why. With xAI, and that’s what our team brings to the table, the algorithms make their prediction and inform the pathologist or the oncologist why they made that prediction. Our team has led the pack in the implementation of xAI in biomedical sciences, specifically in pathology.“
D. Lansing Taylor, PhD, Chairman and Co-founder of SpIntellx and the Director of the University of Pittsburgh Drug Discovery Institute.
“The idea is triaging the patient biopsy samples so they are passed to the expert pathologist to make the final read. HistoMapr can also be used as a training system to support pathologists’ decision making with the help of its xAI feature. This feature could be a game changer for the pathologists in adopting digital pathology.”
Chakra Chennubhotla, PhD, CEO and Co-founder of SpIntellx and Associate Professor at Department of Computational and Systems Biology at the University of Pittsburgh School of Medicine.
“The sciVelo team was instrumental in working with the founders to establish a translational science critical path and to gain support from the CCA for a pilot study on breast biopsies. sciVelo helped us frame a high-impact pitch deck for CCA funding, which we continued to adapt and use for many of our subsequent presentations, including the pitch for seed funding and in the writing of our SBIR Phase I proposal on HistoMapr.”
S. Chakra Chennubhotla, PhD.